Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07131501) titled 'A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma' on Aug. 13.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: The First Affiliated Hospital with Nanjing Medical University
Condition:
Hepatocellular Carcinoma
Immunotherapy
Preoperative
PD-1
CTLA-4
Intervention:
Procedure: Radical surgery
Procedure: TACE treatment
Drug: Iparomlimab a...